Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Apr;6(2):344–351. doi: 10.1016/j.nurt.2009.01.017

Convection-enhanced delivery in the treatment of epilepsy

Michael A Rogawski 1,✉
PMCID: PMC2753495  NIHMSID: NIHMS147017  PMID: 19332329

Summary

Convection-enhanced delivery (CED) is a novel drug-delivery technique that uses positive hydrostatic pressure to deliver a fluid containing a therapeutic substance by bulk flow directly into the interstitial space within a localized region of the brain parenchyma. CED circumvents the blood-brain barrier and provides a wider, more homogenous distribution than bolus deposition (focal injection) or other diffusion-based delivery approaches. A potential use of CED is for the local delivery of antiseizure agents, which would provide an epilepsy treatment approach that avoids the systemic toxicities of orally administered antiepileptic drugs and bystander effects on non-epileptic brain regions. Recent studies have demonstrated that brief CED infusions of nondiffusible peptides that inhibit the release of excitatory neurotransmitters, including ω-conotoxins and botulinum neurotoxins, can produce long-lasting (weeks to months) seizure protection in the rat amygdala-kindling model. Seizure protection is obtainable without detectable neurological or behavioral side effects. Although conventional diffusible antiepileptic drugs do confer seizure protection when administered locally by CED, the effect is transitory. CED is a potential approach for seizure protection that could represent an alternative to resective surgery in the treatment of focal epilepsies that are resistant to orally-administered antiepileptic drugs. The prolonged duration of action of nondiffusible toxins would allow seizure protection to be maintained chronically with infrequent reinfusions.

Key Words: Convection-enhanced delivery, drug delivery, ω-conotoxin, botulinum neurotoxin, kindling, antiepileptic drug, epilepsy, seizure

References

  • 1.Nilsen KE, Cock HR. Focal treatment for refractory epilepsy: hope for the future? Brain Res Brain Res Rev. 2004;44:141–153. doi: 10.1016/j.brainresrev.2003.11.003. [DOI] [PubMed] [Google Scholar]
  • 2.Fisher RS, Chen DK. New routes for delivery of anti-epileptic medications. Acta Neurol Taiwan. 2006;15:225–231. [PubMed] [Google Scholar]
  • 3.Barcia JA, Gallego JM. Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model. Neurotherapeutics. 2009;6:337–343. doi: 10.1016/j.nurt.2009.01.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Anschel DJ, Ortega EL, Kraus AC, Fisher RS. Focally injected adenosine prevents seizures in the rat. Exp Neurol. 2004;190:544–547. doi: 10.1016/j.expneurol.2004.07.017. [DOI] [PubMed] [Google Scholar]
  • 5.Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics. 2008;5:123–127. doi: 10.1016/j.nurt.2007.10.064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ludvig N, Kuzniecky RI, Baptiste SL, et al. Epidural pentobarbital delivery can prevent locally induced neocortical seizures in rats: the prospect of transmeningeal pharmacotherapy for intractable focal epilepsy. Epilepsia. 2006;47:1792–1802. doi: 10.1111/j.1528-1167.2006.00642.x. [DOI] [PubMed] [Google Scholar]
  • 7.John JE, Baptiste SL, Sheffield LG, et al. Transmeningeal delivery of GABA to control neocortical seizures in rats. Epilepsy Res. 2007;75:10–17. doi: 10.1016/j.eplepsyres.2007.03.014. [DOI] [PubMed] [Google Scholar]
  • 8.Ludvig N, Baptiste SL, Tang HM, et al. Localized transmeningeal muscimol prevents neocortical seizures in rats and nonhuman primates: therapeutic implications. Epilepsia 2008 Dec 2 [Epub ahead of print]. [DOI] [PubMed]
  • 9.Kokaia M, Aebischer P, Elmér E, et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp Brain Res. 1994;100:385–394. doi: 10.1007/BF02738399. [DOI] [PubMed] [Google Scholar]
  • 10.Kubek M, Liang D, Byrd K, Domb A. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res. 1998;809:189–197. doi: 10.1016/S0006-8993(98)00860-9. [DOI] [PubMed] [Google Scholar]
  • 11.Tamargo RJ, Rossell LA, Kossoff EH, Tyler BM, Ewend MG, Aryanpur JJ. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res. 2002;48:145–155. doi: 10.1016/S0920-1211(01)00330-8. [DOI] [PubMed] [Google Scholar]
  • 12.López T, Ortiz E, Quintana P, González RD. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain. Colloids Surf A: Physicochem Eng Asp. 2007;300:3–10. doi: 10.1016/j.colsurfa.2006.10.060. [DOI] [Google Scholar]
  • 13.McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther. 2006;14:63–68. doi: 10.1016/j.ymthe.2006.04.004. [DOI] [PubMed] [Google Scholar]
  • 14.Noè F, Pool AH, Nissinen J, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008;131:1506–1515. doi: 10.1093/brain/awn079. [DOI] [PubMed] [Google Scholar]
  • 15.Carpentino JE, Hartman NW, Grabel LB, Naegele JR. Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures. J Neurosci Res. 2008;86:512–524. doi: 10.1002/jnr.21514. [DOI] [PubMed] [Google Scholar]
  • 16.Noé F, Frascal A, Balducci C, et al. Neuropeptide Y overexpression using recombinant adenoassociated viral vectors. Neurotherapeutics. 2009;6:300–306. doi: 10.1016/j.nurt.2009.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.McCown TJ. Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity. Neurotherapeutics. 2009;6:307–311. doi: 10.1016/j.nurt.2009.01.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Old-field EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91:2076–2080. doi: 10.1073/pnas.91.6.2076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg. 1995;82:1021–1029. doi: 10.3171/jns.1995.82.6.1021. [DOI] [PubMed] [Google Scholar]
  • 20.Haroun RI, Brem H. Local drug delivery. Curr Opin Oncol. 2000;12:187–193. doi: 10.1097/00001622-200005000-00001. [DOI] [PubMed] [Google Scholar]
  • 21.Lonser RR, Walbridge S, Garmestani K, et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg. 2002;97:905–913. doi: 10.3171/jns.2002.97.4.0905. [DOI] [PubMed] [Google Scholar]
  • 22.MacKay JA, Deen DF, Szoka FC. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res. 2005;1035:139–153. doi: 10.1016/j.brainres.2004.12.007. [DOI] [PubMed] [Google Scholar]
  • 23.Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994;266:R292–R305. doi: 10.1152/ajpregu.1994.266.1.R292. [DOI] [PubMed] [Google Scholar]
  • 24.Sampson JH, Raghavan R, Brady ML, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 2007;9:343–353. doi: 10.1215/15228517-2007-007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362–1368. doi: 10.1038/nm1297-1362. [DOI] [PubMed] [Google Scholar]
  • 26.Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res. 2000;6:2157–2165. [PubMed] [Google Scholar]
  • 27.Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003;54:479–487. doi: 10.1002/ana.10688. [DOI] [PubMed] [Google Scholar]
  • 28.Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100:472–479. doi: 10.3171/jns.2004.100.3.0472. [DOI] [PubMed] [Google Scholar]
  • 29.Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008;10:320–329. doi: 10.1215/15228517-2008-012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589–595. doi: 10.1038/nm850. [DOI] [PubMed] [Google Scholar]
  • 31.Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–466. doi: 10.1002/ana.20737. [DOI] [PubMed] [Google Scholar]
  • 32.Patel NK, Gill SS. GDNF delivery for Parkinson’s disease. Acta Neurochir Suppl. 2007;97:135–154. doi: 10.1007/978-3-211-33081-4_16. [DOI] [PubMed] [Google Scholar]
  • 33.Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial. Lancet. 2007;369:2097–2105. doi: 10.1016/S0140-6736(07)60982-9. [DOI] [PubMed] [Google Scholar]
  • 34.Marks WJ, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol. 2008;7:400–408. doi: 10.1016/S1474-4422(08)70065-6. [DOI] [PubMed] [Google Scholar]
  • 35.Kaplitt MG, During MJ, inventors. Infusion device and method for infusing material into the brain of a patient. US patent application 2006;0129126 A1 (application 11/280,965).
  • 36.Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg. 2005;103:923–939. doi: 10.3171/jns.2005.103.5.0923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Neeves KB, Lo CT, Foley CP, Saltzman WM, Olbricht WL. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J Control Release. 2006;111:252–362. doi: 10.1016/j.jconrel.2005.11.018. [DOI] [PubMed] [Google Scholar]
  • 38.Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, Gash DM. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol. 2003;461:250–261. doi: 10.1002/cne.10689. [DOI] [PubMed] [Google Scholar]
  • 39.Bennewitz MF, Saltzman WM. Nanotechnology for the delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009;6:323–336. doi: 10.1016/j.nurt.2009.01.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Richardson RM, Larson PS, Bankiewicz KS. Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery. 2008;63:629–644. doi: 10.1227/01.NEU.0000325491.89984.CE. [DOI] [PubMed] [Google Scholar]
  • 41.Smith DC, Krahl SE, Browning RA, Barea EJ. Rapid cessation of focally induced generalized seizures in rats through micro-infusion of lidocaine hydrochloride into the focus. Epilepsia. 1993;34:43–53. doi: 10.1111/j.1528-1157.1993.tb02374.x. [DOI] [PubMed] [Google Scholar]
  • 42.Eder HG, Stein A, Fisher RS. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res. 1997;29:17–24. doi: 10.1016/S0920-1211(97)00061-2. [DOI] [PubMed] [Google Scholar]
  • 43.Eder HG, Jones DB, Fisher RS. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats. Epilepsia. 1997;38:516–521. doi: 10.1111/j.1528-1157.1997.tb01134.x. [DOI] [PubMed] [Google Scholar]
  • 44.Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS. An automated drug delivery system for focal epilepsy. Epilepsy Res. 2000;39:103–114. doi: 10.1016/S0920-1211(99)00107-2. [DOI] [PubMed] [Google Scholar]
  • 45.Gasior M, White NA, Rogawski MA. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists ω-conotoxin GVIA and ω-conotoxin MVIIA. J Pharmacol Exp Ther. 2007;323:458–468. doi: 10.1124/jpet.107.125047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Heiss JD, Walbridge S, Morrison P, et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg. 2005;103:1035–1045. doi: 10.3171/jns.2005.103.6.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Bowersox SS, Luther R. Pharmacotherapeutic potential of ω-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon. 1998;36:1651–1658. doi: 10.1016/S0041-0101(98)00158-5. [DOI] [PubMed] [Google Scholar]
  • 48.Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. Biochemical properties and subcellular distribution of an N-type calcium channel α1 subunit. Neuron. 1992;9:1099–1115. doi: 10.1016/0896-6273(92)90069-P. [DOI] [PubMed] [Google Scholar]
  • 49.Boulton CL, O’Shaughnessy CT. The effect of calcium channel antagonists on spontaneous and evoked epileptiform activity in the rat neocortex in vitro. Eur J Neurosci. 1991;3:992–1000. doi: 10.1111/j.1460-9568.1991.tb00035.x. [DOI] [PubMed] [Google Scholar]
  • 50.Jackson HC, Scheideler MA. Behavioural and anticonvulsant effects of Ca2+ channel toxins in DBA/2 mice. Psychopharmacology (Berl) 1996;126:85–90. doi: 10.1007/BF02246415. [DOI] [PubMed] [Google Scholar]
  • 51.van Luijtelaar G, Wiadema D, Elants C, Scheenen W. Opposite effects of T- and L-type Ca2+ channels blockers in generalized absence epilepsy. Eur J Pharmacol. 2000;406:381–389. doi: 10.1016/S0014-2999(00)00714-7. [DOI] [PubMed] [Google Scholar]
  • 52.Wang S, Ding M, Wu D, Zhan J, Chen Z. ω-Conotoxin MVIIA inhibits amygdaloid kindled seizures in Sprague-Dawley rats. Neurosci Lett. 2007;413:163–167. doi: 10.1016/j.neulet.2006.11.049. [DOI] [PubMed] [Google Scholar]
  • 53.Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother. 2008;9:1575–1583. doi: 10.1517/14656566.9.9.1575. [DOI] [PubMed] [Google Scholar]
  • 54.Verderio C, Pozzi D, Pravettoni E, et al. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron. 2004;41:599–610. doi: 10.1016/S0896-6273(04)00077-7. [DOI] [PubMed] [Google Scholar]
  • 55.Matteoli M, Pozzi D, Grumelli C, et al. The synaptic split of SNAP-25: Different roles in glutamatergic and GABAergic neurons? Neuroscience. 2009;158:223–230. doi: 10.1016/j.neuroscience.2008.03.014. [DOI] [PubMed] [Google Scholar]
  • 56.Verderio C, Grumelli C, Raiteri L, et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic. 2007;8:142–153. doi: 10.1111/j.1600-0854.2006.00520.x. [DOI] [PubMed] [Google Scholar]
  • 57.Costantin L, Bozzi Y, Richichi C, et al. Antiepileptic effects of botulinum neurotoxin E. J Neurosci. 2005;25:1943–1951. doi: 10.1523/JNEUROSCI.4402-04.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Bozzi Y, Costantin L, Antonucci F, Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res. 2006;9:197–203. doi: 10.1007/BF03033939. [DOI] [PubMed] [Google Scholar]
  • 59.Cohen-Gadol AA, Wilhelmi BG, Collignon F, et al. Long-term outcome of epilepsy surgery among 399 patients with nonlesional seizure foci including mesial temporal lobe sclerosis. J Neurosurg. 2006;104:513–524. doi: 10.3171/jns.2006.104.4.513. [DOI] [PubMed] [Google Scholar]
  • 60.Pace JR, Lonser RR, Kirkby RD, Jeffries N, Rogawski MA, Oldfield EH. Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe epilepsy. J Neurosurg. 2002;97:450–454. doi: 10.3171/jns.2002.97.2.0450. [DOI] [PubMed] [Google Scholar]
  • 61.Wiley RG, Kline RH. Neuronal lesioning with axonally transported toxins. J Neurosci Methods. 2000;103:73–82. doi: 10.1016/S0165-0270(00)00297-1. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES